Takara Bio

4974.TPhase 3

Kusatsu, JapanFounded 2002takara-bio.com

Takara Bio is a global biotechnology company with a mission to contribute to the advancement of life sciences and the improvement of human health. It has established itself as a key provider of research reagents, instruments, and contract development and manufacturing (CDMO) services, particularly in the fields of cell and gene therapy. The company's strategic direction focuses on expanding its therapeutic pipeline, scaling its CDMO capabilities, and deepening its research tools portfolio to address growing market demands in precision medicine.

Market Cap

$138.1B

Founded

2002

Employees

1,500-2,000

Focus

Biotech

AI Company Overview

Technology Platform

Integrated platforms for life science research (PCR, NGS, single-cell analysis) and cell/gene therapy development & manufacturing (viral vectors, cell processing, GMP CDMO services).

Pipeline Snapshot

12 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
TBI-1301 + Cyclophosphamide + Fludarabine	Synovial Sarcomas	Phase 3
HF10 plus Ipilimumab	Malignant Melanoma	Phase 2
TBI-1401(HF10) + Ipilimumab	Melanoma Stage III	Phase 2
Nivolumab + HF10	Melanoma	Phase 2
Cyclophosphamide or Bendamustine	Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1/2

Funding History

IPOUndisclosedUndisclosedDec 21, 2004

Opportunities

Takara Bio is poised to capitalize on the explosive growth of the global cell and gene therapy market through its integrated 'tools to therapeutics' model.

Expanding its GMP manufacturing capacity and securing partnerships for its CDMO services present significant revenue growth potential.

Furthermore, successful clinical development and approval of its proprietary cell therapies could open high-value commercial opportunities, particularly in the Asian market.

Risk Factors

Key risks include intense competition in both the reagent and CDMO sectors from larger global players, the high cost and uncertainty of clinical development for its proprietary therapies, and the capital-intensive nature of scaling GMP manufacturing.

Regulatory complexities and evolving reimbursement landscapes for advanced therapies also pose significant challenges.

Competitive Landscape

Takara Bio competes with giants like Thermo Fisher and Qiagen in research tools, and with Lonza and Catalent in the CDMO space. Its differentiation lies in its vertical integration, strong IP in gene delivery (e.g., RetroNectin), and a deep understanding of the Japanese and Asian biotech markets, positioning it as a regional leader with global capabilities.

Publications

Patents

Pipeline